Tuberculosis and Lung Disease for a selective BCG vaccination policy.

Several risk factors have been associated with an increased risk of acquiring tuberculous infection. Among these are immunosuppression, old age, smoking and contact with someone who has infectious TB including through travelling to or living in areas that are highly endemic for TB (>40 cases/100 000 population/year). The latter is reflected in the current UK policy on BCG vaccination which recommends immunisation of all infants (aged 0–12 months) living in areas of the UK where the annual incidence of TB is >40/100 000, all infants (with catch-up to 16 years of age) with a parent or grandparent born in a high-incidence country (annual incidence of TB >40/100 000), new entrants <16 years born in or who have lived for at least 3 months in a high-incidence country, individuals at occupational risk and travellers aged <55 years going to high-incidence areas for >3 months.

Meta-analyses indicate that BCG vaccination is effective in reducing the risk of severe manifestations of TB and that it reduces the risk of acquiring TB in newborns by, on average, 50%. It has been difficult, however, to determine the effect of BCG vaccination on the risk of infection with Mycobacterium tuberculosis because the methods traditionally used for testing (eg, tuberculin skin test) do not distinguish between the effect of BCG vaccination and that of M tuberculosis infection. The interferon-γ release assay (IGRA) is a blood test which measures interferon-γ release of T lymphocytes stimulated by M tuberculosis antigens not present in M bovis BCG. It can therefore detect an immune response to M tuberculosis infection without also including the positive results induced by a prior BCG vaccination. IGRA performed in contacts of patients with infectious pulmonary TB for identification of individuals who have latent M tuberculosis infection is not confounded by prior BCG vaccination as is the tuberculin skin test, making it possible to study the protective effect of BCG against latent tuberculous infection as suggested by recent studies.

In July 2008 the North West London Health Protection Unit (HPU) was contacted about a case of smear-positive pulmonary TB in a UK-born teacher who worked in a nursery in London. The case had been undiagnosed and symptomatic while working in the nursery for 9 months. Public health investigations led to the identification and management of an outbreak in the nursery. This
paper describes the outbreak and assesses whether BCG vaccination has a protective effect against \textit{M tuberculosis} infection.

**METHODS**

**The outbreak**

The index case was a UK-born adult of British white ethnicity. The case was investigated by her GP because of a prolonged history of cough, tiredness and weight loss. The case had no history of travel to high-incidence areas during the last 2 years and had been vaccinated with BCG as a teenager. The case had been suffering from chronic cough and weight loss for 9 months and was initially diagnosed with ‘bronchitis’ before being diagnosed with TB (three sputum samples, all with mucopurulent appearance, acid-fast bacilli seen in all three samples, cultured as fully sensitive \textit{M tuberculosis}, IGRA positive and x-ray changes compatible with pulmonary TB). The case was then immediately started on a 6-month course of antituberculous treatment. Household and close contact tracing was performed and a risk assessment was conducted at her workplace.

The index case was a nursery teacher. Active case finding was conducted where all children and staff who had been exposed in the nursery while the index case was symptomatic were contacted for screening of TB. The screening was conducted according to the ‘stone-in-the-pond’ principle\textsuperscript{13} whereby all close contacts of each new active case of TB were screened.

**The setting**

The workplace of the index case was a private nursery located in one of the most affluent parts of London. More than 90% of the children lived in either Kensington and Chelsea or Westminster boroughs of London, areas with a relatively low incidence of TB (in 2007, 29.1 and 29.9/100 000, respectively) but originated from diverse countries, mostly with a low incidence of TB.

The children who regularly attended the nursery were 2–5 years old, but there was also a weekly 1 h carer and toddler group where each toddler came with an adult carer. The nursery also ran a ‘summer camp’, a day nursery for children who were in London over the summer. The term for all the children had ended just before the index case was diagnosed with TB and the screening of contacts started 6 weeks after the last possible contact with the index case.

All individuals seen at a public hospital in this outbreak were seen at either St Mary’s or Chelsea and Westminster hospitals in London. All IGRA tests were performed at St Mary’s hospital using the QuantiFERON-TB Gold In-Tube assay (Cellestis, Darmstadt, Germany). QuantiFERON uses the region of difference-1 antigen’s early secretory antigen targets 6 (ESAT-6) and TB 7.7, and culture filtrate protein 10 (CFP 10) to stimulate T effector cells specific for \textit{M tuberculosis} to produce interferon-\gamma. Those with a positive IGRA test from any screening round were offered BCG vaccination.

**Definitions**

Close contact: a person with a cumulative total exposure to a smear-positive case of TB exceeding 8 h within a restricted area equivalent to domestic rooms/class rooms.\textsuperscript{5}

Latent \textit{M tuberculosis} infection: in this outbreak, refers to an asymptomatic person with a positive IGRA test and a normal chest x-ray.

Active TB disease: x-ray changes compatible with TB in a person with a positive IGRA test and symptoms of TB where a decision to treat with a full course of antituberculous drugs has been taken, with or without the isolation of \textit{M tuberculosis}.

**RESULTS**

Using the ‘stone-in-the-pond’ approach,\textsuperscript{13} 168 children, 51 staff members and 57 other adults associated with the nursery were screened for TB (figure 1). Among those in whom the BCG vaccination status was known (figure 2), 42% (55/126) of the children and 60% (32/53) of the adults were BCG vaccinated (table 1).

**Univariable analysis**

Among the 168 children, no significant association was found between tuberculous infection and age or sex (table 2). Information on country of birth was available for 66 children, 2 of whom came from a high-incidence country. Being taught by the index case was associated with a positive IGRA test (OR 11.61, 95% CI 3.87 to 34.83) and BCG vaccination showed a protective effect against infection (OR 0.28, 95% CI 0.11 to 0.70, table 2).

Among the 88 adults, no significant association was found between tuberculous infection and BCG vaccination (OR 0.11, 95% CI 0.01 to 1.05).

**Multivariable analysis**

Multivariable analysis was performed for the 168 children. In the fully adjusted model, BCG vaccination showed a significant
protective effect for infection (OR 0.25, 95% CI 0.09 to 0.69). Similarly, being taught by the index case was an independent risk factor for acquiring tuberculous infection (OR 18.91, 95% CI 4.45 to 80.79, table 2).

BCG vaccine effectiveness

Using the adjusted OR for BCG vaccinated children acquiring TB infection, we calculated a corrected risk reduction of 0.34 (95% CI 0.26 to 0.42). Using the formula VE = 1 – RR, this translates into a vaccine effectiveness of 0.66 or 66%, implying that 21 of the 32 infections could have been avoided if all children had been BCG vaccinated.

Microbiological investigations

DNA fingerprinting using the 15 loci-based Mycobacterium Interspersed Repetitive Units Variable Number Tandem Repeats (MIRU-VNTR) typing scheme showed that the M tuberculosis strain (22 253 24 526 14 523, LAM lineage) of the index case was indistinguishable from the strains of two of the adults found to have sputum smear-positive TB. Sputum for culture of M tuberculosis was not available from any of the children.

DISCUSSION

We report extensive transmission of M tuberculosis among very young children with a prolonged exposure to an adult with sputum smear-positive TB. Furthermore, BCG seems to confer a protective effect in children against M tuberculosis infection as assessed by positive IGRA in this cohort.

The UK national BCG immunisation policy was changed in 2005 from universal vaccination of school age children to an approach targeting high-risk infants. This policy change is supported by the International Union against Tuberculosis and Lung Disease consensus statement recommending this change in low-incidence areas, and the change in TB epidemiology from a disease largely affecting the general population to that concentrated in particular high-risk groups. In addition, studies had indicated that the school programme was no longer a cost-effective public health measure and the decline in TB incidence in the UK provided further support for the policy change. Since 1998 the incidence of TB has increased in the UK, although this increase has been predominantly in high-risk groups.

Individual primary care trusts (PCTs) are responsible for the decision to implement universal or targeted BCG vaccination using recommended national criteria. Because of the high overall TB incidence, the diverse population and the large movement within London, more than half of the 26 PCTs in the city have now changed to a universal infant vaccination policy, including some areas with incidence of TB of <40/100 000. Most of the children in our outbreak cohort lived in the PCTs of Westminster and Kensington and Chelsea, both with a TB incidence of <40/100 000. These two PCTs introduced universal BCG vaccination.
Table 1  Number of nursery contacts screened and outcome of the screening

<table>
<thead>
<tr>
<th>Number screened</th>
<th>Contact with index case</th>
<th>Active TB disease</th>
<th>Latent TB infection</th>
<th>Attack rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 (adults)</td>
<td>Teachers</td>
<td>2</td>
<td>7</td>
<td>37.5</td>
</tr>
<tr>
<td>7 (adults)</td>
<td>Guest teachers</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>57 (adults)</td>
<td>Parents and carers</td>
<td>1</td>
<td>5</td>
<td>10.5</td>
</tr>
<tr>
<td>86 (children)</td>
<td>Attended main nursery</td>
<td>7</td>
<td>28</td>
<td>40.7</td>
</tr>
<tr>
<td>30 (children)</td>
<td>Attended summer camp</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>52 (children)</td>
<td>Toddlers attended 1 h per week</td>
<td>2</td>
<td>2</td>
<td>9.4</td>
</tr>
<tr>
<td>256</td>
<td></td>
<td>12</td>
<td>42</td>
<td>21.1</td>
</tr>
</tbody>
</table>

The vaccine effectiveness of 66% found in our study is higher than the 38% reduction in RR found in another UK study9 and the 24% reduction found in a larger and robust study by Soysal et al.12 Overlapping CIs between the studies would suggest that the differences may not be significant. One of the reasons for this difference could be that the other studies investigated latent tuberculous infection in older children who could have acquired their infection prior to the period under investigation in the children. However, the children in the Turkish study12 were also offered BCG vaccination at 2–5 months of age, similar to the children in our study.

Our current knowledge of IGRA tests does not allow distinction between true latent TB infection and lasting immunological responses after exposure to M tuberculosis infection.21 Emerging evidence suggests that an IGRA test may not always correctly predict progression to active TB, but appears to be a more accurate indicator of the presence of latent TB infection than the tuberculin skin test.22 23 However, IGRA testing provides at least the same or possibly higher sensitivity for detecting those who will progress to active TB compared with the tuberculin skin test.22 24 Due to the young age of the children in this cohort, it seems unlikely that exposure prior to this outbreak is sufficient to explain the high probability of a positive IGRA. Nonetheless, data on IGRA in young children are scarce and should be interpreted carefully.21 Only longitudinal follow-up studies will allow us to distinguish the lasting immunological response from latent infection.

Our results suggest that 21 of the 52 paediatric cases of TB infection in this study could have been prevented by BCG vaccination. This should, however, be interpreted with caution. One of the reasons for this difference could be that the other studies investigated latent tuberculous infection in older children who could have acquired their infection prior to the period under investigation in the children. However, the children in the Turkish study12 were also offered BCG vaccination at 2–5 months of age, similar to the children in our study.

Table 2  Association between infection with Mycobacterium tuberculosis and risk factors for the 168 children in the outbreak population

<table>
<thead>
<tr>
<th>BCG vaccinated</th>
<th>Not infected (%)</th>
<th>Infected (%)</th>
<th>Univariate OR (95% CI)</th>
<th>Multivariable OR (95% CI)</th>
<th>p Value (multivariable analysis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (n=53)</td>
<td>46 (87)</td>
<td>6 (11)</td>
<td>1 (2)</td>
<td>0.28 (0.11 to 0.70)</td>
<td>0.25 (0.09 to 0.69)</td>
</tr>
<tr>
<td>No (n=73)</td>
<td>47 (64)</td>
<td>19 (26)</td>
<td>7 (10)</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>NK (n=42)</td>
<td>21 (50)</td>
<td>5 (12)</td>
<td>1 (2)</td>
<td>15 (36)</td>
<td>*</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–2 years (n=77)</td>
<td>58 (75)</td>
<td>9 (12)</td>
<td>4 (5)</td>
<td>6 (8)</td>
<td>*</td>
</tr>
<tr>
<td>3–4 years (n=77)</td>
<td>49 (64)</td>
<td>20 (26)</td>
<td>5 (6)</td>
<td>3 (4)</td>
<td>2.28 (1.05 to 4.92)</td>
</tr>
<tr>
<td>5–9 years (n=4)</td>
<td>3 (75)</td>
<td>1 (25)</td>
<td>0</td>
<td>1.49 (0.14 to 15.47)</td>
<td>0.89 (0.03 to 23.98)</td>
</tr>
<tr>
<td>NK (n=10)</td>
<td>4 (40)</td>
<td>0</td>
<td>0</td>
<td>6 (60)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (n=91)</td>
<td>62 (68)</td>
<td>15 (17)</td>
<td>3 (3)</td>
<td>11 (12)</td>
<td>*</td>
</tr>
<tr>
<td>Female (n=77)</td>
<td>52 (68)</td>
<td>15 (19)</td>
<td>6 (8)</td>
<td>4 (5)</td>
<td>1.39 (0.67 to 2.89)</td>
</tr>
<tr>
<td>Index contact</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (n=86)</td>
<td>49 (57)</td>
<td>28 (33)</td>
<td>7 (8)</td>
<td>2 (2)</td>
<td>11.61 (3.87 to 34.83)</td>
</tr>
<tr>
<td>No (n=82)</td>
<td>65 (79)</td>
<td>2 (2.5)</td>
<td>2 (2.5)</td>
<td>13 (16)</td>
<td></td>
</tr>
</tbody>
</table>

Univariable ORs relate the odds of being an infected contact (as defined by IGRA positivity) for each risk factor. IGRA results are available for 153/168 children. The multivariable ORs are adjusted for all variables shown in the table and include the 123 children for which information was available for all the variables.

*Referent.

NK, not known.
CONCLUSION

We have used IGRA positivity as a measure for *M. tuberculosis* infection and found a protective effect of BCG vaccination. These findings highlight the need to review the evidence for the effectiveness and cost effectiveness of BCG immunisation, in particular with regard to the current TB incidence cut-off level required for universal BCG vaccination in the UK. Owing to the high mobility across the boroughs of the city, we also recommend careful monitoring of TB incidence, BCG vaccination uptake and transfers across PCT boundaries within London among school children. Further research into better markers of latent tuberculosis infection and longitudinal follow-up of exposed individuals is needed to find ways to distinguish individuals latentl infected with live *M. tuberculosis* from those who have persistent antimycobacterial immune responses without an increased risk of ever progressing to TB.

Acknowledgements The authors would like to thank all those who took part in the outbreak investigation, in particular Sheena Basnayake, Lesley Ruta, Marie O'Donoghue, Maria Mercer, the TB and paediatric teams at St Mary's and Chelsea and Westminster hospitals and the rest of the outbreak control team. The authors also thank Professor Paul Fine and Dr Doris Radau for reviewing and commenting on the manuscript.

Competing interests None.

Ethics approval This study was carried out during an outbreak investigation. The Health Protection Agency has Patient Information Advisory Group approval to hold and analyse communicable disease data for public health purposes under Section 60 of the Health and Social Care Act 2001.

Contributors JYC, VM and BW collected the data during the outbreak. EA and SW assessed, diagnosed and treated the children during the outbreak. JE and IA analysed the data. JE and IA designed the analysis protocol. JE, IA and JYC analysed the data. JE, IA and JYC interpreted the data. JE, IA and JYC wrote the paper. JE, IA, JYC, VM, BW, EA and SW interpreted the data. JE, IA, JYC, VM, BW, EA and SW critically reviewed all material. JE and IA are guarantors.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES